Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.6% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

1 of 0 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06860334Phase 2Recruiting

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Role: collaborator

NCT06624787Not ApplicableRecruiting

Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

Role: collaborator

NCT07430501Not Yet Recruiting

Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).

Role: collaborator

NCT04649775Not ApplicableTerminated

AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

Role: collaborator

NCT00199979Phase 3Unknown

Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients

Role: lead

All 5 trials loaded